SG11201608936UA - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr - Google Patents
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgprInfo
- Publication number
- SG11201608936UA SG11201608936UA SG11201608936UA SG11201608936UA SG11201608936UA SG 11201608936U A SG11201608936U A SG 11201608936UA SG 11201608936U A SG11201608936U A SG 11201608936UA SG 11201608936U A SG11201608936U A SG 11201608936UA SG 11201608936U A SG11201608936U A SG 11201608936UA
- Authority
- SG
- Singapore
- Prior art keywords
- asgpr
- dioxabicyclo
- octane
- substituted
- targeting agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/08—Polyoxyalkylene derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462000211P | 2014-05-19 | 2014-05-19 | |
US201462001540P | 2014-05-21 | 2014-05-21 | |
US201562139254P | 2015-03-27 | 2015-03-27 | |
PCT/IB2015/053282 WO2015177668A1 (en) | 2014-05-19 | 2015-05-05 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608936UA true SG11201608936UA (en) | 2016-12-29 |
Family
ID=53200246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608936UA SG11201608936UA (en) | 2014-05-19 | 2015-05-05 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
Country Status (26)
Country | Link |
---|---|
US (5) | US9340553B2 (he) |
EP (1) | EP3145934B1 (he) |
JP (2) | JP6193513B2 (he) |
KR (1) | KR102149572B1 (he) |
CN (1) | CN106459120A (he) |
AU (1) | AU2015262993B2 (he) |
BR (1) | BR112016026809A2 (he) |
CA (1) | CA2891717C (he) |
DK (1) | DK3145934T5 (he) |
ES (1) | ES2841400T3 (he) |
HU (1) | HUE052146T2 (he) |
IL (1) | IL248667B (he) |
MX (1) | MX2016015199A (he) |
MY (1) | MY181586A (he) |
NZ (1) | NZ725600A (he) |
PE (1) | PE20170024A1 (he) |
PH (1) | PH12016502304A1 (he) |
PL (1) | PL3145934T3 (he) |
PT (1) | PT3145934T (he) |
RU (1) | RU2696490C2 (he) |
SA (1) | SA516380328B1 (he) |
SG (1) | SG11201608936UA (he) |
SI (1) | SI3145934T1 (he) |
TW (1) | TWI579286B (he) |
UY (1) | UY36126A (he) |
WO (1) | WO2015177668A1 (he) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
EP3145934B1 (en) | 2014-05-19 | 2020-11-11 | Pfizer Inc | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
US11767301B2 (en) | 2018-04-09 | 2023-09-26 | Yale University | Bi-functional molecules to degrade circulating proteins |
CN109232690A (zh) * | 2018-09-10 | 2019-01-18 | 南方医科大学南方医院 | 一种正电子显像剂标准品前体及其制备方法 |
US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
AU2021213822A1 (en) | 2020-01-31 | 2022-09-22 | Avilar Therapeutics, Inc. | ASGPR-binding compounds for the degradation of extracellular proteins |
IL298406A (he) | 2020-05-22 | 2023-01-01 | Wave Life Sciences Ltd | הרכבי אוליגונוקליאוטידים דו-גדיליים ושיטות הקשורות אליהם |
JP2024503687A (ja) | 2021-01-19 | 2024-01-26 | ノバルティス アーゲー | 細胞外標的の分解 |
KR20240006496A (ko) * | 2021-02-08 | 2024-01-15 | 에멘도바이오 인코포레이티드 | Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, 및 131-138 crispr 뉴클레아제 |
BR112023017702A2 (pt) * | 2021-03-10 | 2023-12-12 | Biohaven Therapeutics Ltd | Degradadores bifuncionais de imunoglobulinas deficientes em galactose |
WO2023009554A1 (en) * | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
EP4392430A1 (en) * | 2021-08-27 | 2024-07-03 | Yale University | Molecular degraders of extracellular proteins |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58121243A (ja) * | 1982-01-12 | 1983-07-19 | Sumitomo Chem Co Ltd | 新規ビシクロオクタン誘導体及びその製造法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5104797A (en) | 1988-05-05 | 1992-04-14 | The Procter & Gamble Company | Process for preparing 5-c-hydroxymethyl aldohexose-based compounds |
US5064672A (en) * | 1988-05-05 | 1991-11-12 | The Procter & Gamble Company | Functional sugar substitutes with reduced calories |
US5041541A (en) * | 1988-05-05 | 1991-08-20 | The Procter & Gamble Company | Functional sugar substituted with reduced calories |
WO1991009537A1 (en) | 1989-12-21 | 1991-07-11 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
JPH06511250A (ja) | 1991-10-04 | 1994-12-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | コレステロール低下化合物及びそれらの製造方法 |
EP1346730A1 (en) * | 1993-12-07 | 2003-09-24 | Neorx Corporation | Pretargeting methods and novel pretargeting conjugates |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
WO2006022325A1 (ja) * | 2004-08-26 | 2006-03-02 | Nippon Shinyaku Co., Ltd. | ガラクトース誘導体、薬物担体及び医薬組成物 |
JP2008540504A (ja) | 2005-05-10 | 2008-11-20 | グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ | 細菌感染症の処置に有用な4’’アミノ結合マクロライド |
WO2007056389A2 (en) | 2005-11-07 | 2007-05-18 | University Of South Carolina | Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
BRPI0918841B8 (pt) * | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
JP2014517032A (ja) | 2011-06-13 | 2014-07-17 | パナセア バイオテック リミテッド | 新規のsglt阻害剤 |
EP2755722B1 (en) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
PT2800811T (pt) | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
CN103570657A (zh) | 2012-07-19 | 2014-02-12 | 天津药物研究院 | 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途 |
WO2014018671A1 (en) * | 2012-07-24 | 2014-01-30 | Regents Of The University Of Minnesota | Therapeutic compounds for the treatment of cancer |
AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
CN103772449B (zh) | 2012-10-26 | 2017-12-26 | 上海阳帆医药科技有限公司 | C‑芳基葡萄糖苷衍生物及其制备方法与用途 |
EP3825401A1 (en) | 2012-12-12 | 2021-05-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP3246324B1 (en) | 2012-12-17 | 2021-08-25 | Tianjin Institute of Pharmaceutical Research | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and uses thereof |
CN103864737B (zh) | 2012-12-17 | 2016-08-17 | 天津药物研究院 | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 |
ES2740299T3 (es) | 2013-03-14 | 2020-02-05 | Msd Int Gmbh | Métodos para preparar inhibidores de SGLT2 |
ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
EP3145934B1 (en) | 2014-05-19 | 2020-11-11 | Pfizer Inc | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
CN104031098A (zh) | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
-
2015
- 2015-05-05 EP EP15724064.9A patent/EP3145934B1/en active Active
- 2015-05-05 SG SG11201608936UA patent/SG11201608936UA/en unknown
- 2015-05-05 AU AU2015262993A patent/AU2015262993B2/en active Active
- 2015-05-05 PE PE2016002255A patent/PE20170024A1/es unknown
- 2015-05-05 HU HUE15724064A patent/HUE052146T2/hu unknown
- 2015-05-05 NZ NZ725600A patent/NZ725600A/en unknown
- 2015-05-05 WO PCT/IB2015/053282 patent/WO2015177668A1/en active Application Filing
- 2015-05-05 ES ES15724064T patent/ES2841400T3/es active Active
- 2015-05-05 RU RU2016142704A patent/RU2696490C2/ru active
- 2015-05-05 MY MYPI2016704172A patent/MY181586A/en unknown
- 2015-05-05 KR KR1020167035265A patent/KR102149572B1/ko active IP Right Grant
- 2015-05-05 PT PT157240649T patent/PT3145934T/pt unknown
- 2015-05-05 DK DK15724064.9T patent/DK3145934T5/da active
- 2015-05-05 MX MX2016015199A patent/MX2016015199A/es unknown
- 2015-05-05 PL PL15724064T patent/PL3145934T3/pl unknown
- 2015-05-05 CN CN201580028359.2A patent/CN106459120A/zh active Pending
- 2015-05-05 SI SI201531464T patent/SI3145934T1/sl unknown
- 2015-05-05 JP JP2016567971A patent/JP6193513B2/ja active Active
- 2015-05-05 BR BR112016026809A patent/BR112016026809A2/pt not_active Application Discontinuation
- 2015-05-15 CA CA2891717A patent/CA2891717C/en active Active
- 2015-05-15 UY UY0001036126A patent/UY36126A/es not_active Application Discontinuation
- 2015-05-15 TW TW104115586A patent/TWI579286B/zh active
- 2015-05-18 US US14/714,484 patent/US9340553B2/en active Active
-
2016
- 2016-04-07 US US15/093,178 patent/US9617293B2/en active Active
- 2016-11-01 IL IL248667A patent/IL248667B/he active IP Right Grant
- 2016-11-17 SA SA516380328A patent/SA516380328B1/ar unknown
- 2016-11-18 PH PH12016502304A patent/PH12016502304A1/en unknown
-
2017
- 2017-02-16 US US15/434,508 patent/US10039778B2/en active Active
- 2017-08-09 JP JP2017154022A patent/JP6663889B2/ja active Active
-
2018
- 2018-06-29 US US16/023,232 patent/US10376531B2/en active Active
-
2019
- 2019-06-24 US US16/450,649 patent/US10813942B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248667B (he) | תרכובות 6,8–דיאוקסביציקלו[3.2.1]אוקטנ–2,3–דיאול מותמרות כחומרים מכווני asgpr | |
GB201512314D0 (en) | Use of a composition containing 1,3-propanediol as an e-liquid | |
IL248324B (he) | דימרים פעילים רוקחית הקשורים דרך קבוצות פנוליק הידרוקסיל | |
HRP20190107T1 (hr) | Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens | |
EP3250030B8 (de) | Landwirtschaftliche maschine | |
ZA201704957B (en) | Composition for the treatment of hepatic veno-occlusive disease | |
MX2017003476A (es) | Compuestos citotoxicos y anti-mitoticos, y metodos para usar los mismos. | |
EP3282848A4 (en) | Agricultural composition | |
DK2904891T3 (da) | Hjul, som danner et forbedret landbrugsredskab | |
EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
DK2904890T3 (da) | Hjul, som danner et forbedret landbrugsredskab | |
PL3017669T3 (pl) | Ulepszone koło rolnicze | |
EP3094347A4 (en) | Methods for enhancing the delivery of active agents | |
EP3215552A4 (en) | Derivatives of 1,3-propanediol | |
EP3362089C0 (en) | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | |
ZA201701714B (en) | Anthostema senegalense-based composition, for use as an anti-aids drug | |
EP3085216B8 (de) | Landwirtschaftliche maschine | |
GB201919175D0 (en) | Cyclopenta[d[pyrimidines and substituted cyclopenta[d[pyrimidines as antitubulin and microtubule targeting agents | |
EP3228316A4 (en) | Composition containing active components of dracocephalum moldavica l. against myocardial ischemia-reperfusion injury | |
HK1244277A1 (zh) | 新的取代的三唑並嘧啶作為抗瘧藥 | |
HUP1600191A2 (en) | Alternative soil preparation, optimalization of biogas preparation | |
AU2014902459A0 (en) | Targeting agents | |
ITBS20140012U1 (it) | Macchina per la preparazione di una bevanda infusa | |
AU2014904352A0 (en) | The Shield, Fit Shield, Fight Shield, Shield Fit or Shield Fight. | |
GB201413121D0 (en) | The E.M.S As Pripulsian |